312 related articles for article (PubMed ID: 26861066)
1. Completeness of serious adverse drug event reports received by the US Food and Drug Administration in 2014.
Moore TJ; Furberg CD; Mattison DR; Cohen MR
Pharmacoepidemiol Drug Saf; 2016 Jun; 25(6):713-8. PubMed ID: 26861066
[TBL] [Abstract][Full Text] [Related]
2. Serious Adverse Drug Events Reported to the FDA: Analysis of the FDA Adverse Event Reporting System 2006-2014 Database.
Sonawane KB; Cheng N; Hansen RA
J Manag Care Spec Pharm; 2018 Jul; 24(7):682-690. PubMed ID: 29952714
[TBL] [Abstract][Full Text] [Related]
3. Assessment of factors associated with completeness of spontaneous adverse event reporting in the United States: A comparison between consumer reports and healthcare professional reports.
Toki T; Ono S
J Clin Pharm Ther; 2020 Jun; 45(3):462-469. PubMed ID: 31765498
[TBL] [Abstract][Full Text] [Related]
4. Impact of a New Consumer Form on the Quantity and Quality of Adverse Event Reports Submitted to the United States Food and Drug Administration.
Muñoz MA; Delcher C; Dal Pan GJ; Kortepeter CM; Wu E; Wei YJ; Xiao H; Winterstein AG
Pharmacotherapy; 2019 Nov; 39(11):1042-1052. PubMed ID: 31479525
[TBL] [Abstract][Full Text] [Related]
5. Quality of serious adverse events reporting to academic sponsors of clinical trials: far from optimal.
Crépin S; Villeneuve C; Merle L
Pharmacoepidemiol Drug Saf; 2016 Jun; 25(6):719-24. PubMed ID: 26887649
[TBL] [Abstract][Full Text] [Related]
6. Reporting of adverse events to MedWatch.
Piazza-Hepp TD; Kennedy DL
Am J Health Syst Pharm; 1995 Jul; 52(13):1436-9. PubMed ID: 7671043
[TBL] [Abstract][Full Text] [Related]
7. Evaluating the completeness and accuracy of MedWatch data.
Getz KA; Stergiopoulos S; Kaitin KI
Am J Ther; 2014; 21(6):442-6. PubMed ID: 23011177
[TBL] [Abstract][Full Text] [Related]
8. Preparation for global introduction of inactivated poliovirus vaccine: safety evidence from the US Vaccine Adverse Event Reporting System, 2000-12.
Iqbal S; Shi J; Seib K; Lewis P; Moro PL; Woo EJ; Shimabukuro T; Orenstein WA
Lancet Infect Dis; 2015 Oct; 15(10):1175-1182. PubMed ID: 26289956
[TBL] [Abstract][Full Text] [Related]
9. An Evaluation of Postmarketing Reports with an Outcome of Death in the US FDA Adverse Event Reporting System.
Marwitz K; Jones SC; Kortepeter CM; Dal Pan GJ; Muñoz MA
Drug Saf; 2020 May; 43(5):457-465. PubMed ID: 31981082
[TBL] [Abstract][Full Text] [Related]
10. [Evaluation of the Association of Hand-Foot Syndrome with Anticancer Drugs Using the US Food and Drug Administration Adverse Event Reporting System (FAERS) and Japanese Adverse Drug Event Report (JADER) Databases].
Sasaoka S; Matsui T; Abe J; Umetsu R; Kato Y; Ueda N; Hane Y; Motooka Y; Hatahira H; Kinosada Y; Nakamura M
Yakugaku Zasshi; 2016; 136(3):507-15. PubMed ID: 26935094
[TBL] [Abstract][Full Text] [Related]
11. Triptans and serious adverse vascular events: data mining of the FDA Adverse Event Reporting System database.
Roberto G; Piccinni C; D'Alessandro R; Poluzzi E
Cephalalgia; 2014 Jan; 34(1):5-13. PubMed ID: 23921799
[TBL] [Abstract][Full Text] [Related]
12. Adverse drug event surveillance and drug withdrawals in the United States, 1969-2002: the importance of reporting suspected reactions.
Wysowski DK; Swartz L
Arch Intern Med; 2005 Jun; 165(12):1363-9. PubMed ID: 15983284
[TBL] [Abstract][Full Text] [Related]
13. Despite 2007 law requiring FDA hotline to be included in print drug ads, reporting of adverse events by consumers still low.
Du D; Goldsmith J; Aikin KJ; Encinosa WE; Nardinelli C
Health Aff (Millwood); 2012 May; 31(5):1022-9. PubMed ID: 22566442
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of Postmarketing Reports from Industry-Sponsored Programs in Drug Safety Surveillance.
Harinstein L; Kalra D; Kortepeter CM; Muñoz MA; Wu E; Dal Pan GJ
Drug Saf; 2019 May; 42(5):649-655. PubMed ID: 30569267
[TBL] [Abstract][Full Text] [Related]
15. Quality assessment of spontaneous triggered adverse event reports received by the Food and Drug Administration.
Brajovic S; Piazza-Hepp T; Swartz L; Dal Pan G
Pharmacoepidemiol Drug Saf; 2012 Jun; 21(6):565-70; discussion 571-2. PubMed ID: 22359404
[TBL] [Abstract][Full Text] [Related]
16. Pediatric Drug Safety Surveillance in FDA-AERS: A Description of Adverse Events from GRiP Project.
de Bie S; Ferrajolo C; Straus SM; Verhamme KM; Bonhoeffer J; Wong IC; Sturkenboom MC;
PLoS One; 2015; 10(6):e0130399. PubMed ID: 26090678
[TBL] [Abstract][Full Text] [Related]
17. Differential completeness of spontaneous adverse event reports among hospitals/clinics, pharmacies, consumers, and pharmaceutical companies in South Korea.
Oh IS; Baek YH; Kim HJ; Lee M; Shin JY
PLoS One; 2019; 14(2):e0212336. PubMed ID: 30763386
[TBL] [Abstract][Full Text] [Related]
18. Patterns in spontaneous adverse event reporting among branded and generic antiepileptic drugs.
Bohn J; Kortepeter C; Muñoz M; Simms K; Montenegro S; Dal Pan G
Clin Pharmacol Ther; 2015 May; 97(5):508-17. PubMed ID: 25670505
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of serious adverse drug reactions: a proactive pharmacovigilance program (RADAR) vs safety activities conducted by the Food and Drug Administration and pharmaceutical manufacturers.
Bennett CL; Nebeker JR; Yarnold PR; Tigue CC; Dorr DA; McKoy JM; Edwards BJ; Hurdle JF; West DP; Lau DT; Angelotta C; Weitzman SA; Belknap SM; Djulbegovic B; Tallman MS; Kuzel TM; Benson AB; Evens A; Trifilio SM; Courtney DM; Raisch DW
Arch Intern Med; 2007 May; 167(10):1041-9. PubMed ID: 17533207
[TBL] [Abstract][Full Text] [Related]
20. Anaphylactoid reactions to Dextran 40 and 70: reports to the United States Food and Drug Administration, 1969 to 2004.
Zinderman CE; Landow L; Wise RP
J Vasc Surg; 2006 May; 43(5):1004-9. PubMed ID: 16678697
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
